Menu Investors Company Overview Overview Press Releases Events + Presentations Company Information Stock Information Analyst Coverage SEC Filings Corporate Governance News Alerts Company Profile Vallon Pharmaceuticals (NASDAQ: VLON) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company’s lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. Leveraging the clinical success of dextroamphetamine, we are developing ADAIR through a streamlined 505(b)(2) U.S. FDA regulatory pathway, which is expected to obviate the need for large Phase 2 and Phase 3 efficacy and safety studies. If approved, ADAIR is expected to be the first abuse-deterrent, immediate-release formulation of dextroamphetamine. Corporate Presentation Download Corporate Presentation Recent Press Releases Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update November 12, 2021 Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event November 11, 2021 Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference November 10, 2021 Contact Us Vallon Pharmaceuticals, Inc. Two Logan Square 100 N. 18th Street, Suite 300 Philadelphia, PA 19103 info@vallon-pharma.com (267) 207-3606 Investor & Media Relations JTC Team, LLC Jenene Thomas (833) 475-8247 vallon@jtcir.com Stock Quote NASDAQ:VLON$4.80▼ $-0.14-2.83% Price $4.80 Change(%) ▼ $-0.14-2.83% Volume 219,846 Open $5.01 Previous Close $4.94 Day Range $4.61-$5.22 52 Week Range $3.61-$10.36 Outstanding 6,812,836 Market Cap 32.702 M Data as of12/03/2021 4:00 PMET Sign Up for Updates © 2021 Vallon Pharmaceuticals | Terms of Use | Privacy Policy ADAIR is an investigational new drug product and has not yet been approved by the FDA. All trademarks shown are the property of their respective owners.

Menu Investors Stock Information Overview Press Releases Events + Presentations Company Information Stock Information Analyst Coverage SEC Filings Corporate Governance News Alerts Stock Quote NASDAQ:VLON$4.80▼ $-0.14-2.83% Price $4.80 Change(%) ▼ $-0.14-2.83% Volume 219,846 Open $5.01 Previous Close $4.94 Day Range $4.61-$5.22 52 Week Range $3.61-$10.36 Outstanding 6,812,836 Market Cap 32.702 M Data as of12/03/2021 4:00 PMET Stock Chart Price VLON NASDAQ: VLON Oct Nov Dec 3 4 5 6 7 8 9 Volume VLON 0 10M 20M Sign Up for Updates © 2021 Vallon Pharmaceuticals | Terms of Use | Privacy Policy ADAIR is an investigational new drug product and has not yet been approved by the FDA. All trademarks shown are the property of their respective owners.